Sugi Predict
/ Targets
/ NEK4
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to NEK4 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression |
PHASE3 | RECRUITING |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL |
PHASE1/PHASE2 | RECRUITING |
| Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer |
PHASE2 | RECRUITING |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer |
PHASE2 | COMPLETED |
| TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer |
PHASE2 | UNKNOWN |
| Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor |
PHASE2 | ACTIVE_NOT_RECRUITING |
| CFI-400945 in Patients With Advanced/Metastatic Breast Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| AZD1775 for Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
PHASE1 | COMPLETED |
| TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy |
PHASE1 | RECRUITING |
| Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel |
PHASE1 | COMPLETED |
| Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
PHASE1 | COMPLETED |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
PHASE1 | COMPLETED |
| A Clinical Study of TQB3824 in Subjects With Advanced Cancer |
PHASE1 | UNKNOWN |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| The Roles of Neutrophil Elastase in Lung Cancer |
nan | UNKNOWN |
| Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients |
nan | RECRUITING |
| Genetics of Neonatal Encephalopathy and Related Disorders |
nan | RECRUITING |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry |
nan | RECRUITING |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy |
nan | UNKNOWN |
| Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma |
nan | COMPLETED |
| Importance of the Microtubule Cytoskeleton in Oocyte Competence |
nan | COMPLETED |
| Protein Intake and Step Reduction in Older Adults |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a NEK4 binder may also engage these)